Category Archives: Cell Biology

Interdisciplinary work highlighted at COVID-19 Research Symposium – The Mix

One participant said, It seems like weve done 10 years of work in seven months!

Kevin Harrod, Ph.D.Jeanne Marrazzo, M.D., director of Infectious Diseases, got a text at the end of Wednesdays four-hour School of Medicine COVID-19 Research Symposium that highlighted the broad and breakneck work done at the University of Alabama at Birmingham since March 2020.

It seems like weve done 10 years of work in seven months! she told participants.

Presentations by eight leading UAB researchers buoyed that sentiment. Among the work:

One hallmark of all eight presentations? An extreme interdisciplinary collaboration of researchers and clinicians across the hospital and university campus, that co-convener Etty Tika Benveniste, Ph.D., called remarkable. Research presented by Fran Lund, Ph.D., for example, involved eight different labs and 30 researchers.

Here are brief highlights of each presentation.

The first two presenters, Lund and Paul Goepfert, M.D., looked at how two kinds of the immune systems white blood cells respond in patients with COVID-19.

Lund, an international expert in B cell biology, was able to isolate B cells from patients that made antibodies against the SARS-CoV-2 virus spike protein. Her team found that many of these antibodies were cross-reactive against the spike proteins from SARS or MERS, which suggested that the antibody protection might wane. She also briefly mentioned her work to test the Altimmune Inc. intranasal vaccine candidate that would be the first intranasal vaccine for COVID-19 and might be effective at preventing transmission.

Steven Rowe, M.D.Goepferts team found a surprising result: Peripheral T follicular helper cells against SARS-CoV-2 continue to increase during convalescence, and they are more activated in severe patients who are in intensive care.

Immunologic studies like those of Lund and Goepfert are vital for understanding how the body responds to SARS-CoV-2 infection, as a prelude to learning how to better treat the disease.

In the section on optimizing diagnosis and treatment, Erdmann talked about several other clinical trials besides the remdesivir trial. He noted that UAB has been quite successful in minority enrollment for inpatient trials, and said UAB researchers have been able to enroll 159 convalescent patients and 846 hospitalized patients for donations of high-quality biological samples like peripheral blood monocytes, blood plasma, urine and oral saline rinses.

After he finished, Marrazzo said, You highlighted the absolutely herculean efforts to do this exceptionally collaborative work at UAB.

Besides the creation and expansion of the UAB COVID-19 test, Leal described how his team was able to adapt that test to screen 250,000 students who were returning to Alabama colleges in August, by using a pooled-sample method. Now, as flu season approaches, the clinical lab is adjusting its test to detect both SARS-CoV-2 and seasonal influenza in a single test. They are also beginning to incorporate prognostic tests of things like interferon-beta or various cytokines into the COVID-19 test. The goal is being able to identify those who are more at risk for severe disease.

In Harrods drug screening, he identified tocopherol polyethylene glycol succinate (TPGS) an existing drug that is a Vitamin E precursor as a drug that acts in synergy with remdesivir. This is important because the TPGS could then lessen the amount of remdesivir needed to treat patients. Remdesivir is in short supply. Intriguingly, his team also found that ivacaftor, a cystic fibrosis drug, is effective against SARS-CoV-2 in the cell culture assays, opening the door to studying its mechanism of action.

The second presenter in basic science discovery, along with Harrod, was Steven Rowe, M.D., director of the Gregory Fleming James Cystic Fibrosis Research Center at UAB. He is testing ferrets as an animal model of severe COVID-19 disease, to fill the urgent need for such a model. His team has found that infection with SARS-CoV-2 disrupts mucociliary clearance in the ferret trachea, as measured by micro-optical coherence tomography, which is similar to the laser eye test that creates a profile of a patients retina. This test is now being adapted to quantify mucociliary clearance the escalator-like movement of mucus from the lungs to the throat in patients with COVID-19.

Paul Goepfert, M.D.,Nathan Erdmann, M.D., Ph.D., and Fran Lund, Ph.D.The final section of the symposium focused on COVID-19 and health disparities.

Mona Fouad, M.D., noted that COVID-19 deaths are higher in African Americans and Hispanics than whites, and she said that, as the pandemic arrived, the UAB Minority Health and Health Disparities team pivoted to COVID-19. They created a Community Mobile Testing Model with three parts: engaging and educating communities about COVID-19 and dispelling myths; bringing mobile testing to vulnerable communities; and creating patient navigators to help people with COVID-19. Navigators are people who have had experiences similar to those of the communitys people and understand their needs.

Jefferson County CARES Act funding expanded the program to 33 test sites in 18 communities in the county. Of the adults tested, Hispanics had a 29 percent positivity rate, African Americans 9 percent and whites 5 percent.

The final UAB presenter was Selwyn Vickers, M.D., dean of the UAB School of Medicine. He said a meeting he had with 13 Black medical leaders nationwide identified COVID-19 as a crisis within a crisis. African Americans already had health disparities, caused in part by disparities in education and socio-economic determinants, before the added burden of a pandemic.

The deadly combination of COVID-19 with the preexisting social determinants was like throwing gasoline on a fire, he said, a combination of smoldering chronic disease and an acute respiratory infection. Even more than African Americans, the worst-hit in the United States are Native Americans.

To help address disparities, Vickers said we need to prepare for a second surge of COVID-19, ensure equitable treatment and vaccine availability, invest in public health, and invest in reducing the social determinants of health disparities.

Mona Fouad, M.D., Selwyn Vickers, M.D., andSixto Leal, M.D., Ph.D.At UAB, Marrazzo is the C. Glenn Cobbs, M.D., Endowed Professor in Infectious Diseases and a professor in the Department of Medicine; Benveniste is the senior vice dean for Basic Sciences in the School of Medicine, the Charlene A. Jones Endowed Chair in Neuroimmunology, and professor, Department of Cell, Developmental and Integrative Biology; Lund is the Charles H. McCauley Professor and chair, Department of Microbiology; Goepfert is director of the Alabama Vaccine Research Clinic and professor, Department of Medicine, Division of Infectious Diseases; and Erdmann is an assistant professor, Department of Medicine, Division of Infectious Diseases.

Also, Leal is assistant professor, Department of Pathology; Harrod is the Benjamin Monroe Carraway Endowed Chair and professor, Department of Anesthesiology and Perioperative Medicine; Rowe is professor, Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine; Fouad is senior associate dean of Diversity and Inclusion, professor, Department of Medicine, and director, Division of Preventive Medicine; and Vickers is the James C. Lee Jr. Endowed Chair, senior vice president for Medicine and dean, School of Medicine.

Go here to read the rest:
Interdisciplinary work highlighted at COVID-19 Research Symposium - The Mix

Cell biologists and bioimaging expert team up to solve fourth dimension secrets – News-Medical.net

Reviewed by Emily Henderson, B.Sc.Oct 29 2020

Cell biologists at the University of Illinois at Urbana-Champaign and Bar-Ilan University at Israel and a bioimaging expert at the University of Central Florida are teaming up in what they hope may lead to a major breakthrough in the understanding of the three-dimensional organization of the nucleus over time and their role in certain diseases.

The dream team was recently awarded a National Institutes of Health $4.2 million grant. The five-year grant is part of the NIH's 4D Nucleome Program (4DN). The program aims to spur the development of technologies that will advance the understanding of how DNA is arranged within cells in space and time and how this affects cellular functions in health and disease.

UCF optics and photonics Assistant Professor Kyu Young Han will develop new multifunctional high-performance microscopes that UIUC's Professor Andrew Belmont and other 4DN researchers will use to map proteins and genes and observe their dynamics in the fourth dimension.

Better understanding of what happens in these tiny places will likely lead to answers for diseases that currently have no treatment and perhaps even cures to others. The challenge is current microscopes lack the kind of power necessary to see detail researchers need in the cell's nucleus.

There are microscopes researchers use right now, but for fulfilling the goals of the 4DN, we need a new type of microscope. They are expensive as well. My team and I are building something that will have several key features, including high-resolution and high-throughput but gentle imaging that doesn't break the bank."

Kyu Young Han, Assistant Professor of Optics and Photonics, University of Central Florida

Han says the two new microscopes will allow Belmont to see proteins and chromosomes within the nucleus moving around in real-time, which will lead to a better understanding of what is going on in gene expression.

Han has an extensive background in chemistry and optical microscopy. He also has some experience in creating new technology with biomedical applications. In 2018 he developed a highly inclined swept tile (HIST) microscope, which can be used for single-molecule imaging in a very large imaging area.

Belmont, from the School of Molecular and Cellular Biology, has been conducting pioneering work in the movement and organization of chromosomes within the nucleus.

Belmont's lab suspects there may be at least two compartments in the nucleus of a cell that are involved in increasing gene expression. One is the nuclear speckle periphery. There may be other places that are critical. To know for sure, they need to be able to observe what is going on, which is why the microscope is so important.

Also on the team, is Yaron Shav-Tal, a researcher at Bar-Ilan University. He will lend his expertise in RNA movement and transport within cells. Together they plan to shed new light on nuclear dynamics and their impact on the biology of gene regulation.

Han is an assistant professor in the College of Optics and Photonics. This is Han's second NIH grant in less than 30 days. Earlier this month he became the university's first faculty member to be awarded the National Institutes of Health's Maximizing Investigators' Research Award for early-stage investigators.

Before joining UCF in 2016, Han worked at the Max Planck Institute in Germany where he studied super-resolution fluorescence imaging.

His postdoctoral research, at the University of Illinois at Urbana-Champaign, focused on designing new optical tools for biological applications, such as studying DNA-protein interactions, RNA imaging in live-cells, and revealing nuclear structure in mammalian cells. He has one patent, which was commercialized by Leica.

Continue reading here:
Cell biologists and bioimaging expert team up to solve fourth dimension secrets - News-Medical.net

Live Cell Imaging Market worth $2.8 billion by 2025 – Exclusive Report by MarketsandMarkets – PRNewswire

CHICAGO, Oct. 29, 2020 /PRNewswire/ -- According to the new market research report "Live Cell Imaging Market by Product (Instruments, Consumables, Software, Services) Application (Cell Biology, Drug Discovery) Technology (Time-lapse Microscopy, FRET) End User (Contract Research Organization, Research Institutes) - Global Forecast to 2025", published by MarketsandMarkets, the global market size is projected to reach USD 2.8 billion by 2025 from USD 1.8 billion in 2020, at a CAGR of 8.8% during the forecast period.

Browse in-depth TOC on "Live Cell Imaging Market"

146 Tables 40 Figures 212 Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163914483

The growing adoption of high-content screening techniques in drug discovery, rising incidence of cancer, and the growth in funding for research are the major factors driving the growth of this market.

"The reagents segment is expected for the largest share of the live cell imaging market in 2019."

Based on type, the live cell imaging consumables market is segmented into reagents, media, assay kits, and other consumables (microplates, slides, Petri dishes, coverslips, and culture chambers). In 2019, the reagents segment accounted for the largest share of 36.1% of the consumables market. The large share of this segment can primarily be attributed to the growing applications of biosciences and biotechnology within the pharmaceutical and healthcare fields. With advancements in technologies, the demand for high-quality reagents in biomedical research and processing is on the rise. The increasing demand for high-quality reagents and their repeated use in live-cell imaging procedures are also factors driving the growth of this market.

By technology, the high-content screening (HCS) segment is expected to grow at the highest CAGR during the forecast period."

Based on technology, the live cell imaging market is segmented into fluorescence resonance energy transfer (FRET), time-lapse microscopy, fluorescence recovery after photobleaching (FRAP), high-content screening (HCS), and other technologies. High-content screening (HCS) segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to the increasing studies on cell behavior and the need to correlate multiple events and markers with cell morphology.

Get 10% Customization on this Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=163914483

"North America to hold the largest regional market share in 2019."

North America is expected to account for the largest share of the live cell imaging market in 2019, followed by Europe. The large share of North America can be attributed to factors such as the availability of government funding for life science research, drug development regulations, advances in live-cell imaging techniques, growth in the biotechnology and pharmaceutical industries, and the rising incidence of cancer.

The prominent players in this live cell imaging market are Danaher Corporation (US), Carl Zeiss AG (Germany), Nikon Corporation (Japan), Olympus Corporation (Japan), PerkinElmer, Inc. (US), GE Healthcare (US), Bruker Corporation (US), Thermo Fisher Scientific Inc. (US), Sartorius AG (Germany), Oxford Instruments (UK), BioTek Instruments (US), Etaluma, Inc. (US), CytoSMART Technologies (Netherlands), NanoEnTek Inc. (Korea), Phase Focus Limited (UK), Tomocube, Inc. (South Korea), Phase Holographic Imaging PHI AB (Sweden), BD Biosciences (US), Sony Biotechnology, Inc. (US), Merck KGaA (Germany), KEYENCE Corporation (Japan), ibidi GmbH (Germany), Bio-Rad Laboratories (US), Logos Biosystems (South Korea), and Nanolive SA (Switzerland).

Browse Adjacent Markets: Biotechnology Market ResearchReports & Consulting

Get Special Pricing on Bundle Reports: https://www.marketsandmarkets.com/RequestBundleReport.asp?id=163914483

Browse Related Reports:

Cell Culture Market by Product (Consumables (Media, FBS), Equipment (Bioreactor, Centrifuge, Incubator, Microscope, Autoclave)), Application (Stem Cell, Vaccines, Therapeutic proteins), End User (Pharma, Research Institutes) - Global Forecast to 2024

https://www.marketsandmarkets.com/Market-Reports/cell-culture-market-media-sera-reagents-559.html

Cell-based Assay Market by Product (Reagents, Microplates, Cell Lines, Assay Kits, Instruments, Services), Application (Drug Discovery, Research), End User (CROs, Biopharma Companies, Research Institutes), Geography - Global Forecast to 2024

https://www.marketsandmarkets.com/Market-Reports/cell-based-assays-market-119917269.html

About MarketsandMarkets

MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:Mr. Aashish MehraMarketsandMarkets INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: [emailprotected] Research Insight: https://www.marketsandmarkets.com/ResearchInsight/live-cell-imaging-market.aspVisit Our Web Site: https://www.marketsandmarkets.comContent Source: https://www.marketsandmarkets.com/PressReleases/live-cell-imaging.asp

SOURCE MarketsandMarkets

See the article here:
Live Cell Imaging Market worth $2.8 billion by 2025 - Exclusive Report by MarketsandMarkets - PRNewswire

Role of Serotonin in The Developing Brain – BioTechniques.com

Researchers have identified a potential new role for the neurotransmitter serotonin that could explain a heretofore unknown evolutionary mystery.

Over the course of human evolution, the brain in particular the neocortex grew larger than our primate relatives, enabling us to think, speak and dream. The underlying mechanism of this neocortical expansion is unclear, with a number of potential molecular players having been identified. Each identified molecule is believed to act intrinsically in the basal progenitor cells of the developing neocortex, influencing its growth.

Now, researchers from the Max Planck Institute of Molecular Cell Biology and Genetics (Dresden, Germany) have identified serotonin as an additional player in this evolutionary expansion. In contrast to the previously identified molecules, serotonin is thought to act extrinsically to the progenitor cells, behaving as a growth factor in the developing brain.

Depression and anxiety: what is the scientific difference?

The biochemical differences between depression and anxiety have been elucidated, providing new insights for targeting treatment.

Placenta-derived serotonin reaches the brain via blood circulation and has been identified in both human and mice embryos, though its function in the developing brain remained a mystery. In the recent study, researchers identified the receptor HTR2A, which is found in human but not mice neocortices, leading the team to believe it may play a role in the development of the larger human brain. Indeed, when mice were genetically engineered to express the HTR2A receptor, they were found to develop much larger than normal neocortices.

We found that serotonin, by activating this receptor, caused a chain of reactions that resulted in the production of more basal progenitors in the developing brain. More basal progenitors can then increase the production of cortical neurons, which paves the way to a bigger brain, explained lead author Lei Xing.

Abnormal signaling of serotonin and a disturbed expression or mutation of its receptor HTR2A have been observed in various neurodevelopmental and psychiatric disorders, such as Down syndrome, attention deficit hyperactivity disorder and autism, commented research team leader Wieland Huttner. Our findings may help explain how malfunctions of serotonin and its receptor during fetal brain development can lead to congenital disorders and may suggest novel approaches for therapeutic avenues.

Follow this link:
Role of Serotonin in The Developing Brain - BioTechniques.com

bit.bio + London Institute for Mathematical Sciences = progress on industrial-scale production of all human cells – Cambridge Independent

A combination of mathematics and biology could enable industrial-scale production of all human cells for drug discovery or cell therapy - and accelerate the introduction of prototype organ printing.

That is the hope of cell coding company bit.bio, which has agreed a new partnership with the London Institute for Mathematical Sciences.

Helping to reduce reliance on animal testing, the organisations expect clinical trials of therapies based on bit.bios cells to be rolled out in three to five years.

Prototype organ printing could happen within 10 years, they hope.

Dr Mark Kotter, founder and CEO of bit.bio , said: Our collaboration with the London Institute is incredibly exciting, as we work on a paradigm shift in biology, moving it from an observational to a predictive science.

Over the past decade we have learned that biology can be viewed as a software. Our collaboration with LIMS will help to decode the operating system of life. This will unlock opportunities, including a new generation of cell therapies for tackling diseases such as cancer and dementia, accelerating drug development and could even help us combat pandemics of the future.

It has been a landmark year for bit.bio, which closed a $41.5million Series A investment in June , backed by former National Cancer Institute director Richard Klausner, among others.

The company, which also moved to new headquarters on Babraham Research Campus, has already created the first large-scale, high-purity batches of cells to test new Alzheimers and dementia drugs.

We are just at that critical time in biology where weve identified a huge bottleneck, which really consists of having access to a robust and scalable source of human cells, said Mark.

At bit.bio we combine data science and biology to make cells that nobody else can make.

The starting point for this is a platform technology that we call optio-x, which essentially allows us to execute genetic code in cells very robustly.

In order to be able to recreate every human cell, you need to create a model or an understanding of this operating system, which is our collaboration with LIMS.

Once youve got that you can also create a predictive model of a cell.

Mark sees biology increasingly moving towards engineering - a transition that has already taken place successfully in physics.

If you think about it, when Newton introduced calculus to physics, he gave us a tool to look into the future and in biology we are still at a point where we do experiments to generate data and we have very limited ways of predicting the outcome of an experiment.

If we had a better understanding of the control mechanisms of biology - I would say the software that runs in a human cell - then we would be able to also pivot biology into that new paradigm, he said.

Drugs tested on animals have a 97 per cent failure rate, partly due to differences between animal and human cells.

And progress on cell therapies for diseases such as cancer have been hampered by the lack of available human cells.

While synthetic biology has promised to overcome some of these challenges, it has been hindered by the difficulty in unlocking the fundamental laws governing cell identity.

But bit.bio has succeeded in creating high-purity batches of neurons, muscle cells and oligodendrocytes at scale and its patented technique holds the potential for the custom-building of any human cell.

With backing from Silicon Valley, and a scientific team including Dr Roger Pedersen, a pioneer of human stem cell biology and cell reprogramming expert Dr Marius Wernig, co-director of the Stanford Stem Cell Institute, it is poised to make a pioneering contribution.

The moonshot goal of bit.bio is to recreate every human cell in the body and then to provide them for research and drug discovery purposes, said Mark.

But at the same time there will be cell types that are going to be very valuable for therapeutic application in the form of cell therapies and perhaps in the future tissues or organs.

Bit.bios partnership with The London Institute for Mathematical Sciences, a private physics and maths research centre, aims to continue the fusion of biology and maths, so that all human cells can be read out and reprogrammed like software.

Dr Thomas Fink, founder and director of the London institute for Mathematical Sciences, said: Life is the final frontier of mathematics and the marriage of maths and biology will change the face of both disciplines.

Decoding cellular identity will require entirely new kinds of mathematics, as well as a deeper understanding of machine learning. Living organisms exhibit extraordinary concision and elegance, the hallmarks off mathematical structure.

The human genome amounts to just three gigabytes of data. But viruses, a mere seven kilobytes, can redirect it by calling up just the right subroutines, in a similar way to how modular software works. Uncovering the operating system of life could enable us to engineer human cells as readily as we do software.

Bit.bio is a nominee in the Cambridge Independent Science and Technology Awards. A shortlist will be announced in November, ahead of the winners being revealed early in 2021.

Read more

Beautiful science in operating system of life underpins $41.5m investment in bit.bio

Meet bit.bio as cell coding firm retires the Elpis Biomed name

Elpis BioMed: Mastering the art of reprogramming human cells

Read more from the original source:
bit.bio + London Institute for Mathematical Sciences = progress on industrial-scale production of all human cells - Cambridge Independent

2020 Dickson Prize in Medicine Awarded to Pioneer Researcher in Synthetic Biology – Newswise

Newswise PITTSBURGH, Oct. 26, 2020 James J. Collins, Ph.D., an innovator in synthetic biology whose ideas have contributed to novel diagnostics and treatments targeting infections and complex diseases, has been awarded the 2020 Dickson Prize in Medicine, the University of Pittsburgh School of Medicines highest honor.

The prize is given annually to an American biomedical researcher who has made significant, progressive contributions to medicine. The award consists of a specially commissioned medal, a $50,000 honorarium and an invitation to present the keynote lecture during the Universitys annual campus-wide showcase of scientific research. Due to the COVID-19 pandemic, both the annual showcase and Collins lecture have been postponed until 2021 at a date to be determined.

Dr. Collins is defining whats possible in the disciplines of synthetic and systems biology. His highly creative work applying engineering design principles to molecular biology has generated numerous new diagnostics and therapeutics with wide application to medicine, said Anantha Shekhar, M.D., Ph.D., Pitts senior vice chancellor for the health sciences and John and Gertrude Petersen Dean of Medicine. It is our honor to recognize him with the School of Medicines most prestigious award.

Im grateful to work with outstanding lab members and collaborators whose dedication and insight have been critical to what weve achieved, said Collins, who is the Termeer Professor of Medical Engineering and Science in the Department of Biological Engineering at Massachusetts Institute of Technology and is affiliated faculty with the Broad Institute of MIT and Harvard University, and the Wyss Institute at Harvard. I am thrilled and honored to receive the Dickson Prize in Medicine.

A seminal 2000 publication describing the successful creation of a stable, synthetic gene circuit in Escherichia coli bacteria has been cited more than 4,000 times and marked the arrival of an important new discipline in biomedicine. Collins later demonstrated that synthetic gene networks could be linked with a cells genetic circuitry as a regulatory mechanism to create programmable cells for biomedical applications.

More recently, Collins has created engineered microbes and whole-cell biosensors to serve as in vivo diagnostics and therapeutics. One innovative platform that he and colleagues developed embeds freeze-dried, cell-free synthetic gene networks onto paper and other materials with a wide range of potential clinical and research applications.

The resulting materials contain properties of a living cell, are stable at room temperature and can be activated by simply adding water. Collinss work on freeze-dried, cell-free synthetic biology has established a platform for a new class of rapid, programmable in vitro diagnostics for emerging pathogens, including drug-resistant bacteria and viruses. Collins and his team currently are developing a rapid self-activating COVID-19 face mask as a wearable diagnostic.

Collins earned an A.B. in physics at the College of the Holy Cross in Worcester, Mass., before completing a Ph.D. in medical engineering at the University of Oxford with the distinction of Rhodes Scholar. He has received a MacArthur Foundation Genius award, NIH Directors Pioneer Award and Sanofi-Institut Pasteur Award. Collins is an elected member of the National Academy of Sciences, National Academy of Engineering, National Academy of Medicine and the American Academy of Arts and Sciences. He is a charter fellow of the National Academy of Inventors.

To read this release online or share it, visit http://www.upmc.com/media/news/102620-Dickson-Prize-2020.

Read more from the original source:
2020 Dickson Prize in Medicine Awarded to Pioneer Researcher in Synthetic Biology - Newswise

Insitro and BMS Team Up to Pave the Way for New ALS and FTD Treatments – BioSpace

Insitro founder and CEO Daphne Koller (left) and CFO Mary Rozenman (right). Photo courtesy of Insitro.

San Francisco-based Insitro announced today that it has entered a five-year discovery collaboration agreement with Bristol Myers Squibb to discover and develop novel therapies for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Through this collaboration, Insitro will utilize its proprietary platform, Insitro Human (ISH), to create induced pluripotent stem cell (iPSC) derived disease models for both diseases. This platform applies machine learning, human genetics and functional genomics to create predictive in vitro models. ISH can potentially provide insight into how these diseases progress within patients. Bristol Myers Squibb will have the option to select from targets identified by Insitro to advance through clinical development and commercialization.

Neurodegenerative disorders like ALS and FTD have historically been a challenging therapeutic area, with no disease modifying treatments today. We are excited to partner with Bristol Myers Squibb and its world-class neuroscience leaders, who share our vision of leveraging human genetics, machine learning, and high-throughput biology and chemistry in order to identify and provide new treatments for patients suffering from these devastating diseases, said Daphne Koller, founder and chief executive officer of Insitro. Since founding Insitro just over two years ago, we have demonstrated our capabilities in building predictive models to discover novel targets and patient segments. We have also developed new approaches to machine-learning-enabled therapeutics design, which we look forward to deploying to discover treatments for novel targets emerging from this collaboration.

Insitro is set to receive $50 million as an upfront payment, and it will be eligible to receive an additional $20 million in near term operational milestones.

We believe that machine learning and data generated by novel experimental platforms offer the opportunity to rethink how we discover and design novel medicines, said Richard Hargreaves, Ph.D., senior vice president, head of neuroscience TRC research and early development, Bristol Myers Squibb. There is an unmet medical need for therapies to treat ALS and FTD and we are excited by the prospect of working with Insitros team towards our shared goal of identifying transformative treatments for patients with these devastating diseases.

Insitro recently strengthened its machine learning-based drug discovery capabilities through the acquisition of Haystack Sciences back on Oct. 22. Haystack focuses on synthesizing, breeding and analyzing large, diverse combinatorial chemical libraries encoded by unique DNA sequences called DNA-encoded libraries (DELs). Insitro intends on leveraging the DEL technology to collect massive small molecule data.

We are thrilled to have the Haystack team join Insitro, Koller said at the time of the announcement. For the past two years, Insitro has been building a company focused on the creation of predictive cell-based models of disease in order to enable the discovery of novel targets and evaluate the benefits of new or existing molecules in genetically defined patient segments. This acquisition enables us to expand our capabilities to the area of therapeutic design and advances us towards our goal of leveraging machine learning across the entire process of designing and developing better medicines for patients.

Haystacks platform combines several elements, including the capability to synthesize small molecule collections. With these advantages, Insitro will be better equipped to develop multi-dimensional predictive models for small molecule design.

I am excited by the opportunity to join a company with such a uniquely open and collaborative culture and to work with and learn from colleagues in data science, machine learning, automation and cell biology, said Richard E. Watts, co-founder and chief executive officer of Haystack Sciences. The capabilities enabled by joining our efforts are considerably greater than the sum of the parts, and I look forward to helping build core drug discovery efforts at Insitro.

Read this article:
Insitro and BMS Team Up to Pave the Way for New ALS and FTD Treatments - BioSpace

Bill Gates-Backed Ginkgo Bioworks Has A New $40 Million Spinout Using Synthetic Biology To Clean Wastewater – Forbes

Nicole Richards, CEO of Allonnia.

Nature has a remarkable ability to recycle. It can break apart complex organic materials into simpler compounds. Then nature will re-use those substances to build plants and animals.

Last week, Allonnia launched with $40 million in funding to engineer and commercialize microbes to eliminate pollutants in wastewater and soil.

"The waste problem is vast and growing, and impacts the health of our planet and everyone," said Nicole Richards who joined Allonnia as CEO after a stint at Dupont. "Luckily, nature already uses microbes to break down waste. Allonnia will be accelerating and scaling natural processes to develop new breakthroughs and increase the efficiency of waste remediation."

Allonnia is the third company to launch out of the Ferment Consortium, Ginkgo Bioworks' $350 million investment vehicle leveraging biology to solve global challenges and transform established industries. Ferment Consortium companies Joyn Bio, Motif Foodworks, and now Allonnia will utilize Ginkgo's foundry for biological engineering, its iterative codebase model, and an extensive industry network of partners and investors.

The company is also backed by Bill Gates' Cascade Investments, Battelle, General Atlantic, and Viking Global Investors.

Manufacturers have started looking at their waste streams differently. The business community has learned that reducing waste - including toxic waste - often means less cost. Reducing waste could also increase efficiencies and boost profits. Taking a cue from nature - where there is no waste - manufacturers are beginning to look at their waste streams as potential assets.

The potential to treat industrial wastewater and land treatment, improve oil and gas processing, impact plastics degradation, and recycle consumer goods is worth hundreds of billions of dollars globally. Richards, who last served as growth, strategy, and M&A director of Water Solutions at Dupont, saw an opportunity.

"Waste pollution is one of the most pivotal environmental issues impacting public and planetary health. Traditional solutions have reached their limit," continued Richards. "Microbes' ability to break down substances have always made them appealing for waste remediation. Our job at Allonnia will be to accelerate and scale the natural process of breaking down waste while increasing efficiency and sustainability."

Allonnia targets a class of man-made chemicals known as PFAs, which are found in a wide range of consumer products that people use daily including food packaging, non-stick pots and pans, and water repellent fabrics. Some of the most commonly used PFAs have long lives, earning the name "the forever chemicals."

Allonnia aims to change the current trajectory of waste management, by leveraging Ginkgo's platform and recent advances in protein engineering and cell design to develop microbial and enzymatic solutions that destroy environmental contaminants. Allonnia also aims to recover and upcycle critical elements found in waste streams such as manufacturing waste, catalyst recovery, and electronic components. Many of these materials are difficult to mine and costly to recycle using traditional methods. Allonnia will design biological processes to specifically and selectively recover valuable elements in complex waste streams to make them reusable for future manufacturing processes.

Richards believes Allonia has the opportunity to change how we view waste. "We consider waste to be a failure of the human imagination. Allonnia will bring the power of synthetic biology tools to revolutionize the waste markets and address problems where new approaches are badly needed. Our vision is a waste- and pollution-free world. Our contribution will be mitigating the damage that has been done and helping create a better world for the future."

Im the founder of SynBioBeta, and some of the companies that I write aboutincluding Ginkgo Bioworksare sponsors of the SynBioBeta conference and weekly digest. Thank you to Karl Schmieder for additional research and reporting in this article.

Read more:
Bill Gates-Backed Ginkgo Bioworks Has A New $40 Million Spinout Using Synthetic Biology To Clean Wastewater - Forbes

Scientists discover new organic compounds that could have helped form the first cells – Newswise

Newswise Chemists studying how life started often focus on how modern biopolymers like peptides and nucleic acids contributed, but modern biopolymers don't form easily without help from living organisms. A possible solution to this paradox is that life started using different components, and many non-biological chemicals were likely abundant in the environment. A new survey conducted by an international team of chemists from the Earth-Life Science Institute (ELSI) at Tokyo Institute of Technology and other institutes from Malaysia, the Czech Republic, the US and India, has found that a diverse set of such compounds easily form polymers under primitive environmental conditions, and some even spontaneously form cell-like structures.

Understanding how life started on Earth is one of the most challenging questions modern science attempts to explain. Scientists presently study modern organisms and try to see what aspects of their biochemistry are universal, and thus were probably present in the organisms from which they descended. The best guess is that life has thrived on Earth for at least 3.5 billion of Earth's 4.5 billion year history since the planet formed, and most scientists would say life likely began before there is good evidence for its existence. Problematically, since Earth's surface is dynamic, the earliest traces of life on Earth have not been preserved in the geological record. However, the earliest evidence for life on Earth tells us little about what the earliest organisms were made of, or what was going on inside their cells. "There is clearly a lot left to learn from prebiotic chemistry about how life may have arisen," says the study's co-author Jim Cleaves.

A hallmark of life is evolution, and the mechanisms of evolution suggest that common traits can suddenly be displaced by rare and novel mutations which allow mutant organisms to survive better and proliferate, often replacing previously common organisms very rapidly. Paleontological, ecological and laboratory evidence suggests this occurs commonly and quickly. One example is an invasive organism like the dandelion, which was introduced to the Americas from Europe and is now a common weed causing lawn-concerned homeowners to spend countless hours of effort and dollars to eradicate. Another less whimsical example is COVID-19, a virus (technically not living, but technically an organism) which was probably confined to a small population of bats for years, but suddenly spread among humans around the world. Organisms which reproduce faster than their competitors, even only slightly faster, quickly send their competitors to what Leon Trotsky termed the "ash heap of history." As most organisms which have ever existed are extinct, co-author Tony Z. Jia suggests that "to understand how modern biology emerged, it is important to study plausible non-biological chemistries or structures not currently present in modern biology which potentially went extinct as life complexified."

This idea of evolutionary replacement is pushed to an extreme when scientists try to understand the origins of life. All modern organisms have a few core commonalities: all life is cellular, life uses DNA as an information storage molecule, and uses DNA to make ribonucleic RNA as an intermediary way to make proteins. Proteins perform most of the catalysis in modern biochemistry, and they are created using a very nearly universal "code" to make them from RNA. How this code came to be is in itself enigmatic, but these deep questions point to their possibly having been a very murky period in early biological evolution ~ 4 billion years ago during which almost none of the molecular features observed in modern biochemistry were present, and few if any of the ones that were present have been carried forward.

Proteins are linear polymers of amino acids. These floppy strings of polymerised amino acids fold into unique three-dimensional shapes, forming extremely efficient catalysts which foster precise chemical reactions. In principle, many types of polymerised molecules could form similar strings and fold to form similar catalytic shapes, and synthetic chemists have already discovered many examples. "The point of this kind of study is finding functional polymers in plausibly prebiotic systems without the assistance of biology, including grad students," says co-author Irena Mamajanov.

Scientists have found many ways to make biological organic compounds without the intervention of biology, and these mechanisms help explain these compounds' presence in samples like carbonaceous meteorites, which are relics of the early solar system, and which scientists don't think ever hosted life. These primordial meteorite samples also contain many other types of molecules which could have formed complex folded polymers like proteins, which could have helped steer primitive chemistry. Proteins, by virtue of their folding and catalysis mediate much of the complex biochemical evolution observed in living systems. The ELSI team reasoned that alternative polymers could have helped this occur before the coding between DNA and protein evolved. "Perhaps we cannot reverse-engineer the origin of life; it may be more productive to try and build it from scratch, and not necessarily using modern biomolecules. There were large reservoirs of non-biological chemicals that existed on the primeval Earth. How they helped in the formation of life-as-we-know-it is what we are interested in," says co-author Kuhan Chandru.

The ELSI team did something simple yet profound: they took a large set of structurally diverse small organic molecules which could plausibly be made by prebiotic processes and tried to see if they could form polymers when evaporated from dilute solution. To their surprise, they found many of the primitive compounds could, though they also found some of them decomposed rapidly. This simple criterion, whether a compound is able to be dried without decomposing, may have been one of the earliest evolutionary selection pressures for primordial molecules.

The team conducted one further simple test. They took these dried reactions, added water and looked at them under a microscope. To their surprise, some of the products of these reaction formed cell-sized compartments. That simple starting materials containing 10 to 20 atoms can be converted to self-organised cell-like aggregates containing millions of atoms provides startling insight into how simple chemistry may have led to complex chemistry bordering on the kind of complexity associated with living systems, while not using modern biochemicals.

"We didn't test every possible compound, but we tested a lot of possible compounds. The diversity of chemical behaviors we found was surprising, and suggests this kind of small-molecule to functional-aggregate behavior is a common feature of organic chemistry, which may make the origin of life a more common phenomenon than previously thought," concludes co-author Niraja Bapat.

###

Tokyo Institute of Technology (Tokyo Tech)stands at the forefront of research and higher education as the leading university for science and technology in Japan. Tokyo Tech researchers excel in fields ranging from materials science to biology, computer science, and physics. Founded in 1881, Tokyo Tech hosts over 10,000 undergraduate and graduate students per year, who develop into scientific leaders and some of the most sought-after engineers in industry. Embodying the Japanese philosophy of "monotsukuri," meaning "technical ingenuity and innovation," the Tokyo Tech community strives to contribute to society through high-impact research.

The Earth-Life Science Institute (ELSI)is one of Japan's ambitious World Premiere International research centers, whose aim is to achieve progress in broadly inter-disciplinary scientific areas by inspiring the world's greatest minds to come to Japan and collaborate on the most challenging scientific problems. ELSI's primary aim is to address the origin and co-evolution of the Earth and life.

The World Premier International Research Center Initiative (WPI)was launched in 2007 by the Ministry of Education, Culture, Sports, Science and Technology (MEXT) to help build globally visible research centers in Japan. These institutes promote high research standards and outstanding research environments that attract frontline researchers from around the world. These centers are highly autonomous, allowing them to revolutionise conventional modes of research operation and administration in Japan.

Continued here:
Scientists discover new organic compounds that could have helped form the first cells - Newswise

Characterization of Pancreatic Cancer Cells Response to Peptigels that Mimic Healthy and Tumor Tissue Properties – News-Medical.net

Research focusing on how cells communicate with their environment is crucial for a greater understanding of intracellular processes, and this field has been highly active in cancer and cell biology. Contemporary matrices that are used to investigate these interactions now contain tunable mechanical and biochemical characteristics.

The extracellular matrix (ECM) in tissues of various cellular environments and organs have highly dissimilar chemical properties, for example, in charge, ionic strength, ECM ligands, and pH. Substrates that are available at present do not provide the biochemical and mechanical tuneability that is required to mimic and reproduce cancer tissues.

PeptiGels are peptide hydrogels created by Manchester BIOGEL and critially they are fully-defined and anmial free. Interestingly their mechanical and biochemical properties are tunable which means they can be varied systematically to create scaffolds that mimic healthy and tumour tissue, as well as mimic differing stages of tumour development.For example scaffoldscan be prepared to independantly vary pH (betweenpH 7.4 and 6.0)and stiffness (between 1 and 20 kPa) which enables imitation ofthe range for cancerous and healthy tissues for both parameters.

A novel range of applications in cancer and mechanobiology can be created through the ability to modulate biochemical and mechanical properties at the same time.

The majority of solid carcinomas, for example, Pancreatic Ductal Adenocarcinoma (PDAC), are distinguished by the emergence of a large quantity of fibrous or connective tissue around the tumor, which regulates their resistance to chemotherapy, inhibits drug delivery, and controls the growth and spread of tumors.

This fibrous, acidic tissue influences cancer cell behavior in their ability to survive and proliferate.

We were excited to use Manchester BIOGELS PeptiGels as a platform for cell biology studies and essentially tailor the hydrogel properties to mimic the mechanical and chemical environment of both healthy and cancer tissue. We went onto explore independently the influence of each on cell activation, survival and growth and are now investigating details mechanotransduction on signaling pathways.

Dr Armando Del Rio Hernandez, Department of Bioengineering, Imperial College London

Image Credit: Manchester BIOGEL

The images present immunofluorescent staining of a Pancreatic Adenocarcinoma Suit-2 cell line cultured on alpha 2 (stiff, tumor mimicking) and gamma 2 (healthy, soft tissue mimicking) peptide gels with normal (7.4) and low (6.0) pH.

The Pancreatic Ductal Adenocarcinoma suit-2 cells exhibit a biochemical response as a result of the stiff and acidic (tumor mimicking peptide gels), which creates an increase in proliferation (Ki67 marker where the increased expression is highlighted with white arrows).

PeptiGel matrices provide the ability to discover details of the mechanotransduction signaling pathways which influence the survival and activation of cancer cells.

The most recent results from this project, funded by Innovate KTP (KTP12102), can be found at http://biomechanicalregulation-lab.org.

Over 15 years ago, Professors Aline Miller and Alberto Saiani at The University of Manchester synthesised a self-assembling oligo-peptide with interesting gelation properties. This work started with a small grant from the University.

Over subsequent years, the team meticulously crafted and studied self-assembling peptides to perfect their platform technology and produce a range of hydrogels ideal for 3D cell culture. In 2014, due to a demand for their materials, our company, Manchester BIOGEL was founded to enable these hydrogels to be readily available to researchers wishing to create new opportunities in the high-growth fields of 3D cell culture, 3D bioprinting and medical devices. Since opening our doors, we have supported scientists in the UK and beyond to create optimal environments for a wide variety of cell types.

Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Follow this link:
Characterization of Pancreatic Cancer Cells Response to Peptigels that Mimic Healthy and Tumor Tissue Properties - News-Medical.net